| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
1 Department of Molecular and Integrative Physiology, University of Illinois and College of Medicine, Urbana, Illinois, and 2 Women’s Health Research Institute, Wyeth Research, Collegeville, Pennsylvania
Selective estrogen receptor modulators (SERMs) such as tamoxifen are effective in the treatment of many estrogen receptor-positive breast cancers and have also proven to be effective in the prevention of breast cancer in women at high risk for the disease. The comparative abilities of tamoxifen versus raloxifene in breast cancer prevention are currently being compared in the Study of Tamoxifen and Raloxifene trial. To better understand the actions of these compounds in breast cancer, we have examined their effects on the expression of 
12,000 genes, using Affymetrix GeneChip microarrays, with quantitative PCR verification in many cases, categorizing their actions as agonist, antagonist, or partial agonist/antagonist. Analysis of gene stimulation and inhibition by the SERMs trans-hydroxytamoxifen (TOT) and raloxifene (Ral) or ICI 182,780 (ICI) and by estradiol (E2) in estrogen receptor-containing MCF-7 human breast cancer cells revealed that (a) TOT was the most E2-like of the three compounds, (b) all three compounds either partially or fully antagonized the action of E2 on most genes, with the order of antagonist activity being ICI > Ral > TOT, (c) TOT and Ral, but not ICI, displayed partial agonist/partial antagonist activity on a number of E2-regulated genes, (d) several stimulatory cell cycle-related genes were down-regulated exclusively by ICI, (e) the estrogen-like activity of Ral nearly always overlapped with that of TOT, indicating that Ral has little unique agonist activity different from that of TOT, and (f) some genes were specifically up-regulated by TOT but not Ral, ICI, or E2. Hence, gene expression profiling can discern fundamental differences among SERMs and provides insight into the distinct biologies of TOT, Ral, and ICI in breast cancer.
This article has been cited by other articles:
|
|
 |
|
  S. Ahmed, E. Valen, A. Sandelin, and J. Matthews Dioxin Increases the Interaction Between Aryl Hydrocarbon Receptor and Estrogen Receptor Alpha at Human Promoters Toxicol. Sci., October 1, 2009; 111(2): 254 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pusztai, J.-H. Jeong, Y. Gong, J. S. Ross, C. Kim, S. Paik, R. Rouzier, F. Andre, G. N. Hortobagyi, N. Wolmark, et al. Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial J. Clin. Oncol., September 10, 2009; 27(26): 4287 - 4292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Miller, M. Perez-Torres, A. Narasanna, M. Guix, O. Stal, G. Perez-Tenorio, A. M. Gonzalez-Angulo, B. T. Hennessy, G. B. Mills, J. P. Kennedy, et al. Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer Cancer Res., May 15, 2009; 69(10): 4192 - 4201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Wickramasinghe, T. T. Manavalan, S. M. Dougherty, K. A. Riggs, Y. Li, and C. M. Klinge Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells Nucleic Acids Res., May 1, 2009; 37(8): 2584 - 2595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Stossi, Z. Madak-Erdogan, and B. S. Katzenellenbogen Estrogen Receptor Alpha Represses Transcription of Early Target Genes via p300 and CtBP1 Mol. Cell. Biol., April 1, 2009; 29(7): 1749 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wu, I. Ivanov, R. Xu, and S. Safe Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studies J. Mol. Endocrinol., January 1, 2009; 42(1): 19 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frasor, A. E. Weaver, M. Pradhan, and K. Mehta Synergistic Up-Regulation of Prostaglandin E Synthase Expression in Breast Cancer Cells by 17{beta}-Estradiol and Proinflammatory Cytokines Endocrinology, December 1, 2008; 149(12): 6272 - 6279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Alfinito, X. Chen, J. Atherton, S. Cosmi, and D. C. Deecher ICI 182,780 Penetrates Brain and Hypothalamic Tissue and Has Functional Effects in the Brain after Systemic Dosing Endocrinology, October 1, 2008; 149(10): 5219 - 5226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yasuhara, G. R. O. Gomes, E. R. Siu, C. I. Suenaga, E. Marostica, C. S. Porto, and M. F. M. Lazari Effects of the Antiestrogen Fulvestrant (ICI 182,780) on Gene Expression of the Rat Efferent Ductules Biol Reprod, September 1, 2008; 79(3): 432 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Barnett, S. Sheng, T. Howe Charn, A. Waheed, W. S. Sly, C.-Y. Lin, E. T. Liu, and B. S. Katzenellenbogen Estrogen Receptor Regulation of Carbonic Anhydrase XII through a Distal Enhancer in Breast Cancer Cancer Res., May 1, 2008; 68(9): 3505 - 3515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, S. Masri, S. Phung, and S. Chen The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop Cancer Res., April 1, 2008; 68(7): 2259 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Levy, D. Tatomer, C. B. Herber, X. Zhao, H. Tang, T. Sargeant, L. J. Ball, J. Summers, T. P. Speed, and D. C. Leitman Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene Mol. Endocrinol., February 1, 2008; 22(2): 287 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Higgins, S. Liu, M. Abdelrahim, K. Vanderlaag, X. Liu, W. Porter, R. Metz, and S. Safe Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17{beta}-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins Mol. Endocrinol., February 1, 2008; 22(2): 388 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cheng, D. V. Yu, J.-H. Zhou, and D. J. Shapiro Tamoxifen Induction of CCAAT Enhancer-binding Protein {alpha} Is Required for Tamoxifen-induced Apoptosis J. Biol. Chem., October 19, 2007; 282(42): 30535 - 30543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Stender, J. Frasor, B. Komm, K. C. N. Chang, W. L. Kraus, and B. S. Katzenellenbogen Estrogen-Regulated Gene Networks in Human Breast Cancer Cells: Involvement of E2F1 in the Regulation of Cell Proliferation Mol. Endocrinol., September 1, 2007; 21(9): 2112 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J Su, Y.-H. Cheng, R. T Chatterton, Z.-H. Lin, P. Yin, S. Reierstad, J. Innes, and S. E Bulun Regulation of 17-Beta Hydroxysteroid Dehydrogenase Type 2 in Human Placental Endothelial Cells Biol Reprod, September 1, 2007; 77(3): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mita, Z. Zhang, Y. Ando, T. Toyama, M. Hamaguchi, S. Kobayashi, S.-i. Hayashi, Y. Fujii, H. Iwase, and H. Yamashita Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast Cancer Jpn. J. Clin. Oncol., August 3, 2007; (2007) hym066v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Schultz-Norton, V. A. Gabisi, Y. S. Ziegler, I. X. McLeod, J. R. Yates, and A. M. Nardulli Interaction of estrogen receptor {alpha} with proliferating cell nuclear antigen Nucleic Acids Res., August 1, 2007; 35(15): 5028 - 5038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al. Estrogen Receptors: How Do They Signal and What Are Their Targets Physiol Rev, July 1, 2007; 87(3): 905 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Schultz-Norton, K. A. Walt, Y. S. Ziegler, I. X. McLeod, J. R. Yates, L. T. Raetzman, and A. M. Nardulli The Deoxyribonucleic Acid Repair Protein Flap Endonuclease-1 Modulates Estrogen-Responsive Gene Expression Mol. Endocrinol., July 1, 2007; 21(7): 1569 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Johnson, M. Maleki-Dizaji, J. A Styles, and I. N H White Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen Endocr. Relat. Cancer, June 1, 2007; 14(2): 337 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-C. Leung, J. Brce, N. Doyle, H. J. Lee, G. M. Leong, K. Sjogren, and K. K. Y. Ho Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases Endocrinology, May 1, 2007; 148(5): 2417 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Andre, C. Hatzis, K. Anderson, C. Sotiriou, C. Mazouni, J. Mejia, B. Wang, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2061 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fan, P. S. Yan, C. Hartman-Frey, L. Chen, H. Paik, S. L. Oyer, J. D. Salisbury, A. S.L. Cheng, L. Li, P. H. Abbosh, et al. Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant Cancer Res., December 15, 2006; 66(24): 11954 - 11966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M W Gee, V E Shaw, S E Hiscox, R A McClelland, N K Rushmere, and R I Nicholson Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S77 - S88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Jaber, T. Gao, L. Huang, S. Karmakar, and C. L. Smith The Pure Estrogen Receptor Antagonist ICI 182,780 Promotes a Novel Interaction of Estrogen Receptor-{alpha} with the 3',5'-Cyclic Adenosine Monophosphate Response Element-Binding Protein-Binding Protein/p300 Coactivators Mol. Endocrinol., November 1, 2006; 20(11): 2695 - 2710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, September 29, 2006; 313(5795): 1929 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shioda, J. Chesnes, K. R. Coser, L. Zou, J. Hur, K. L. Dean, C. Sonnenschein, A. M. Soto, and K. J. Isselbacher Importance of dosage standardization for interpreting transcriptomal signature profiles: Evidence from studies of xenoestrogens PNAS, August 8, 2006; 103(32): 12033 - 12038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Lim, L. Li, Z. Desta, Q. Zhao, J. M. Rae, D. A. Flockhart, and T. C. Skaar Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frasor, E. C. Chang, B. Komm, C.-Y. Lin, V. B. Vega, E. T. Liu, L. D. Miller, J. Smeds, J. Bergh, and B. S. Katzenellenbogen Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res., July 15, 2006; 66(14): 7334 - 7340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Woditschka, J. D. Haag, J. L. Waller, D. M. Monson, A. A. Hitt, H. L. Brose, R. Hu, Y. Zheng, P. A. Watson, K. Kim, et al. Neu-Induced Retroviral Rat Mammary Carcinogenesis: A Novel Chemoprevention Model for Both Hormonally Responsive and Nonresponsive Mammary Carcinomas. Cancer Res., July 1, 2006; 66(13): 6884 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stossi, V. S. Likhite, J. A. Katzenellenbogen, and B. S. Katzenellenbogen Estrogen-occupied Estrogen Receptor Represses Cyclin G2 Gene Expression and Recruits a Repressor Complex at the Cyclin G2 Promoter J. Biol. Chem., June 16, 2006; 281(24): 16272 - 16278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C L Wilson, A H Sims, A Howell, C J Miller, and R B Clarke Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr. Relat. Cancer, June 1, 2006; 13(2): 617 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Olivier, P. Close, E. Castermans, L. de Leval, S. Tabruyn, A. Chariot, M. Malaise, M.-P. Merville, V. Bours, and N. Franchimont Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-{kappa}B Inhibition and Gene Expression Signature Mol. Pharmacol., May 1, 2006; 69(5): 1615 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. E. Harvell, J. K. Richer, D. C. Allred, C. A. Sartorius, and K. B. Horwitz Estradiol Regulates Different Genes in Human Breast Tumor Xenografts Compared with the Identical Cells in Culture Endocrinology, February 1, 2006; 147(2): 700 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. W. Fleming, T. E. Spencer, S. H. Safe, and F. W. Bazer Estrogen Regulates Transcription of the Ovine Oxytocin Receptor Gene through GC-Rich SP1 Promoter Elements Endocrinology, February 1, 2006; 147(2): 899 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Yager and N. E. Davidson Estrogen Carcinogenesis in Breast Cancer N. Engl. J. Med., January 19, 2006; 354(3): 270 - 282. [Full Text] [PDF]
|
|
|
|
|
|
S C J P Gielen, L C M Kuhne, P C Ewing, L J Blok, and C W Burger Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study Endocr. Relat. Cancer, December 1, 2005; 12(4): 1037 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C.J.P. Gielen, C. W. Burger, L. C.M. Kuhne, P. Hanifi-Moghaddam, and L. J. Blok Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin Reproductive Sciences, October 1, 2005; 12(7): e55 - e66. [Abstract] [PDF]
|
|
|
|
|
|
J. Frasor, J. M. Danes, C. C. Funk, and B. S. Katzenellenbogen Estrogen down-regulation of the corepressor N-CoR: Mechanism and implications for estrogen derepression of N-CoR-regulated genes PNAS, September 13, 2005; 102(37): 13153 - 13157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ivanova, K. M. Dobrzycka, S. Jiang, K. Michaelis, R. Meyer, K. Kang, B. Adkins, O. A. Barski, S. Zubairy, J. Divisova, et al. Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction Mol. Cell. Biol., April 15, 2005; 25(8): 2995 - 3006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H K Kinyamu, J Chen, and T K Archer Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors J. Mol. Endocrinol., April 1, 2005; 34(2): 281 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Itoh, K. Karlsberg, I. Kijima, Y.-C. Yuan, D. Smith, J. Ye, and S. Chen Letrozole-, Anastrozole-, and Tamoxifen-Responsive Genes in MCF-7aro Cells: A Microarray Approach Mol. Cancer Res., April 1, 2005; 3(4): 203 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
J A Vendrell, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, and P A Cohen Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines Endocr. Relat. Cancer, March 1, 2005; 12(1): 75 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Varshochi, F. Halim, A. Sunters, J. P. Alao, P. A. Madureira, S. M. Hart, S. Ali, D. M. Vigushin, R. C. Coombes, and E. W.-F. Lam ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor {alpha} from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line J. Biol. Chem., February 4, 2005; 280(5): 3185 - 3196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. DeNardo, H.-T. Kim, S. Hilsenbeck, V. Cuba, A. Tsimelzon, and P. H. Brown Global Gene Expression Analysis of Estrogen Receptor Transcription Factor Cross Talk in Breast Cancer: Identification of Estrogen-Induced/Activator Protein-1-Dependent Genes Mol. Endocrinol., February 1, 2005; 19(2): 362 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells Endocrinology, February 1, 2005; 146(2): 889 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Labhart, S. Karmakar, E. M. Salicru, B. S. Egan, V. Alexiadis, B. W. O'Malley, and C. L. Smith Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator PNAS, February 1, 2005; 102(5): 1339 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fan, H. Nakshatri, and K. P. Nephew Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor-{alpha} Activation Mol. Endocrinol., November 1, 2004; 18(11): 2603 - 2615. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
